MilliporeSigma
  • Home
  • Search Results
  • Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis.

Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis.

Scientific reports (2017-08-20)
Tatiana Altadill, Tyrone M Dowdy, Kirandeep Gill, Armando Reques, Smrithi S Menon, Cristian P Moiola, Carlos Lopez-Gil, Eva Coll, Xavier Matias-Guiu, Silvia Cabrera, Angel Garcia, Jaume Reventos, Stephen W Byers, Antonio Gil-Moreno, Amrita K Cheema, Eva Colas
ABSTRACT

Endometrial cancer (EC) remains the most common malignancy of the genital tract among women in developed countries. Although much research has been performed at genomic, transcriptomic and proteomic level, there is still a significant gap in the metabolomic studies of EC. In order to gain insights into altered metabolic pathways in the onset and progression of EC carcinogenesis, we used high resolution mass spectrometry to characterize the metabolomic and lipidomic profile of 39 human EC and 17 healthy endometrial tissue samples. Several pathways including lipids, Kynurenine pathway, endocannabinoids signaling pathway and the RNA editing pathway were found to be dysregulated in EC. The dysregulation of the RNA editing pathway was further investigated in an independent set of 183 human EC tissues and matched controls, using orthogonal approaches. We found that ADAR2 is overexpressed in EC and that the increase in expression positively correlates with the aggressiveness of the tumor. Furthermore, silencing of ADAR2 in three EC cell lines resulted in a decreased proliferation rate, increased apoptosis, and reduced migration capabilities in vitro. Taken together, our results suggest that ADAR2 functions as an oncogene in endometrial carcinogenesis and could be a potential target for improving EC treatment strategies.

MATERIALS
Product Number
Brand
Product Description

Ishikawa Cell Line human, 99040201, endometrial adenocarcinoma
Sigma-Aldrich
Glutaraldehyde solution, Grade II, 25% in H2O
Sigma-Aldrich
MISSION® esiRNA, targeting human CHN1
Sigma-Aldrich
MISSION® esiRNA, targeting human ADARB1
Sigma-Aldrich
Monoclonal Anti-ADAR antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0176, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
MISSION® esiRNA, targeting human ADAR